Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients
Three patients with different clinical symptoms of graft‐versus‐host disease (GVHD) who had received donor lymphocyte transfusion (DLT) for the treatment of relapsed leukaemia after an allogeneic bone marrow transplantation (BMT) from HLA‐matched sibling donors were analysed for the presence of solu...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 1999-03, Vol.104 (4), p.795-800 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 800 |
|---|---|
| container_issue | 4 |
| container_start_page | 795 |
| container_title | British journal of haematology |
| container_volume | 104 |
| creator | Das, Hiranmoy Imoto, Shion Murayama, Tohru Kajimoto, Kazuyoshi Sugimoto, Takeshi Isobe, Takashi Nakagawa, Toshitaro Nishimura, Ryuichiro Koizumi, Tamio |
| description | Three patients with different clinical symptoms of graft‐versus‐host disease (GVHD) who had received donor lymphocyte transfusion (DLT) for the treatment of relapsed leukaemia after an allogeneic bone marrow transplantation (BMT) from HLA‐matched sibling donors were analysed for the presence of soluble FasL (sFasL) in the sera and for the expression of the Fas ligand (FasL) gene in the peripheral blood mononuclear cells (PBMNC). Two patients who demonstrated liver damage with increased levels of serum bilirubin showed significantly increased levels of serum sFasL. The increase in the sFasL level was observed prior to the increase in the bilirubin during the clinical courses of both patients. The high dose of methyl predonisolone administered to one of these patients greatly reduced the levels of sFasL in the serum. The bilirubin levels were also reduced thereafter. The third patient (without liver damage) did not show any increase in the serum sFasL level.
The expression of the FasL gene in the PBMNC of these three patients was examined. All three patients showed increased levels of the FasL gene expression during their clinical courses. However, only one patient showed a parallel alteration of FasL gene expression with sFasL in the serum. These cases provide evidence that the Fas/FasL system is closely associated with human GVHD, especially in the development of liver GVHD. |
| doi_str_mv | 10.1046/j.1365-2141.1999.01246.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69670452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69670452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5106-41907bbc18f333e2b942832796ff203a56fd95a8dcdbc285706d889e1e8d888a3</originalsourceid><addsrcrecordid>eNqNkMtu1DAUhi1ERYfCKyAvELsEX3KxFyygUEoViU1ZW058PM0okwSfpJ3u4A14Rp6kDhkVlqzOL_v7feSPEMpZyllWvN2lXBZ5InjGU661ThkXWZEenpDN48VTsmGMlUksqFPyHHHHGJcs58_IKWdciywTG_KzglvokA6e4tDNdQf0wmJFbe_WsIUeKBzGAIjt0FM3h7bf0ukGqFuqw7iHflr622D99PvHr1sIOGMMNwNO1LUIFoG2Pf1YXcfTKYCdwNHRTm1s4gty4m2H8PI4z8i3i0_X55dJ9fXzl_P3VdLknBVJxjUr67rhykspQdQ6E0qKUhfeCyZtXninc6tc4-pGqLxkhVNKAwcVp7LyjLxZ3x3D8H0GnMy-xQa6zvYwzGgKXZQsy0UE1Qo2YUAM4M0Y2r0N94Yzs-g3O7NYNotls-g3f_SbQ6y-Ou6Y6z24f4qr7wi8PgIWG9v5YPumxb9cKeI_F-zdit21Hdz_937z4epySfIBmfOkOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69670452</pqid></control><display><type>article</type><title>Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><creator>Das, Hiranmoy ; Imoto, Shion ; Murayama, Tohru ; Kajimoto, Kazuyoshi ; Sugimoto, Takeshi ; Isobe, Takashi ; Nakagawa, Toshitaro ; Nishimura, Ryuichiro ; Koizumi, Tamio</creator><creatorcontrib>Das, Hiranmoy ; Imoto, Shion ; Murayama, Tohru ; Kajimoto, Kazuyoshi ; Sugimoto, Takeshi ; Isobe, Takashi ; Nakagawa, Toshitaro ; Nishimura, Ryuichiro ; Koizumi, Tamio</creatorcontrib><description>Three patients with different clinical symptoms of graft‐versus‐host disease (GVHD) who had received donor lymphocyte transfusion (DLT) for the treatment of relapsed leukaemia after an allogeneic bone marrow transplantation (BMT) from HLA‐matched sibling donors were analysed for the presence of soluble FasL (sFasL) in the sera and for the expression of the Fas ligand (FasL) gene in the peripheral blood mononuclear cells (PBMNC). Two patients who demonstrated liver damage with increased levels of serum bilirubin showed significantly increased levels of serum sFasL. The increase in the sFasL level was observed prior to the increase in the bilirubin during the clinical courses of both patients. The high dose of methyl predonisolone administered to one of these patients greatly reduced the levels of sFasL in the serum. The bilirubin levels were also reduced thereafter. The third patient (without liver damage) did not show any increase in the serum sFasL level.
The expression of the FasL gene in the PBMNC of these three patients was examined. All three patients showed increased levels of the FasL gene expression during their clinical courses. However, only one patient showed a parallel alteration of FasL gene expression with sFasL in the serum. These cases provide evidence that the Fas/FasL system is closely associated with human GVHD, especially in the development of liver GVHD.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1046/j.1365-2141.1999.01246.x</identifier><identifier>PMID: 10192442</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, U.K. and Cambridge, USA: Blackwell Science Ltd</publisher><subject>Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; BMT, DLT ; Bone Marrow Transplantation - methods ; Fas Ligand Protein ; FasL gene expression ; Female ; Graft vs Host Disease - etiology ; GVHD ; Humans ; Leukemia - therapy ; Lymphocyte Transfusion - adverse effects ; Male ; Medical sciences ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - metabolism ; Monocytes - metabolism ; Recurrence ; RNA, Messenger - metabolism ; sFasL ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>British journal of haematology, 1999-03, Vol.104 (4), p.795-800</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5106-41907bbc18f333e2b942832796ff203a56fd95a8dcdbc285706d889e1e8d888a3</citedby><cites>FETCH-LOGICAL-c5106-41907bbc18f333e2b942832796ff203a56fd95a8dcdbc285706d889e1e8d888a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2141.1999.01246.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2141.1999.01246.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1724192$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10192442$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Das, Hiranmoy</creatorcontrib><creatorcontrib>Imoto, Shion</creatorcontrib><creatorcontrib>Murayama, Tohru</creatorcontrib><creatorcontrib>Kajimoto, Kazuyoshi</creatorcontrib><creatorcontrib>Sugimoto, Takeshi</creatorcontrib><creatorcontrib>Isobe, Takashi</creatorcontrib><creatorcontrib>Nakagawa, Toshitaro</creatorcontrib><creatorcontrib>Nishimura, Ryuichiro</creatorcontrib><creatorcontrib>Koizumi, Tamio</creatorcontrib><title>Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Three patients with different clinical symptoms of graft‐versus‐host disease (GVHD) who had received donor lymphocyte transfusion (DLT) for the treatment of relapsed leukaemia after an allogeneic bone marrow transplantation (BMT) from HLA‐matched sibling donors were analysed for the presence of soluble FasL (sFasL) in the sera and for the expression of the Fas ligand (FasL) gene in the peripheral blood mononuclear cells (PBMNC). Two patients who demonstrated liver damage with increased levels of serum bilirubin showed significantly increased levels of serum sFasL. The increase in the sFasL level was observed prior to the increase in the bilirubin during the clinical courses of both patients. The high dose of methyl predonisolone administered to one of these patients greatly reduced the levels of sFasL in the serum. The bilirubin levels were also reduced thereafter. The third patient (without liver damage) did not show any increase in the serum sFasL level.
The expression of the FasL gene in the PBMNC of these three patients was examined. All three patients showed increased levels of the FasL gene expression during their clinical courses. However, only one patient showed a parallel alteration of FasL gene expression with sFasL in the serum. These cases provide evidence that the Fas/FasL system is closely associated with human GVHD, especially in the development of liver GVHD.</description><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>BMT, DLT</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Fas Ligand Protein</subject><subject>FasL gene expression</subject><subject>Female</subject><subject>Graft vs Host Disease - etiology</subject><subject>GVHD</subject><subject>Humans</subject><subject>Leukemia - therapy</subject><subject>Lymphocyte Transfusion - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Monocytes - metabolism</subject><subject>Recurrence</subject><subject>RNA, Messenger - metabolism</subject><subject>sFasL</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtu1DAUhi1ERYfCKyAvELsEX3KxFyygUEoViU1ZW058PM0okwSfpJ3u4A14Rp6kDhkVlqzOL_v7feSPEMpZyllWvN2lXBZ5InjGU661ThkXWZEenpDN48VTsmGMlUksqFPyHHHHGJcs58_IKWdciywTG_KzglvokA6e4tDNdQf0wmJFbe_WsIUeKBzGAIjt0FM3h7bf0ukGqFuqw7iHflr622D99PvHr1sIOGMMNwNO1LUIFoG2Pf1YXcfTKYCdwNHRTm1s4gty4m2H8PI4z8i3i0_X55dJ9fXzl_P3VdLknBVJxjUr67rhykspQdQ6E0qKUhfeCyZtXninc6tc4-pGqLxkhVNKAwcVp7LyjLxZ3x3D8H0GnMy-xQa6zvYwzGgKXZQsy0UE1Qo2YUAM4M0Y2r0N94Yzs-g3O7NYNotls-g3f_SbQ6y-Ou6Y6z24f4qr7wi8PgIWG9v5YPumxb9cKeI_F-zdit21Hdz_937z4epySfIBmfOkOA</recordid><startdate>199903</startdate><enddate>199903</enddate><creator>Das, Hiranmoy</creator><creator>Imoto, Shion</creator><creator>Murayama, Tohru</creator><creator>Kajimoto, Kazuyoshi</creator><creator>Sugimoto, Takeshi</creator><creator>Isobe, Takashi</creator><creator>Nakagawa, Toshitaro</creator><creator>Nishimura, Ryuichiro</creator><creator>Koizumi, Tamio</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199903</creationdate><title>Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients</title><author>Das, Hiranmoy ; Imoto, Shion ; Murayama, Tohru ; Kajimoto, Kazuyoshi ; Sugimoto, Takeshi ; Isobe, Takashi ; Nakagawa, Toshitaro ; Nishimura, Ryuichiro ; Koizumi, Tamio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5106-41907bbc18f333e2b942832796ff203a56fd95a8dcdbc285706d889e1e8d888a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>BMT, DLT</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Fas Ligand Protein</topic><topic>FasL gene expression</topic><topic>Female</topic><topic>Graft vs Host Disease - etiology</topic><topic>GVHD</topic><topic>Humans</topic><topic>Leukemia - therapy</topic><topic>Lymphocyte Transfusion - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Monocytes - metabolism</topic><topic>Recurrence</topic><topic>RNA, Messenger - metabolism</topic><topic>sFasL</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Das, Hiranmoy</creatorcontrib><creatorcontrib>Imoto, Shion</creatorcontrib><creatorcontrib>Murayama, Tohru</creatorcontrib><creatorcontrib>Kajimoto, Kazuyoshi</creatorcontrib><creatorcontrib>Sugimoto, Takeshi</creatorcontrib><creatorcontrib>Isobe, Takashi</creatorcontrib><creatorcontrib>Nakagawa, Toshitaro</creatorcontrib><creatorcontrib>Nishimura, Ryuichiro</creatorcontrib><creatorcontrib>Koizumi, Tamio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Das, Hiranmoy</au><au>Imoto, Shion</au><au>Murayama, Tohru</au><au>Kajimoto, Kazuyoshi</au><au>Sugimoto, Takeshi</au><au>Isobe, Takashi</au><au>Nakagawa, Toshitaro</au><au>Nishimura, Ryuichiro</au><au>Koizumi, Tamio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>1999-03</date><risdate>1999</risdate><volume>104</volume><issue>4</issue><spage>795</spage><epage>800</epage><pages>795-800</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Three patients with different clinical symptoms of graft‐versus‐host disease (GVHD) who had received donor lymphocyte transfusion (DLT) for the treatment of relapsed leukaemia after an allogeneic bone marrow transplantation (BMT) from HLA‐matched sibling donors were analysed for the presence of soluble FasL (sFasL) in the sera and for the expression of the Fas ligand (FasL) gene in the peripheral blood mononuclear cells (PBMNC). Two patients who demonstrated liver damage with increased levels of serum bilirubin showed significantly increased levels of serum sFasL. The increase in the sFasL level was observed prior to the increase in the bilirubin during the clinical courses of both patients. The high dose of methyl predonisolone administered to one of these patients greatly reduced the levels of sFasL in the serum. The bilirubin levels were also reduced thereafter. The third patient (without liver damage) did not show any increase in the serum sFasL level.
The expression of the FasL gene in the PBMNC of these three patients was examined. All three patients showed increased levels of the FasL gene expression during their clinical courses. However, only one patient showed a parallel alteration of FasL gene expression with sFasL in the serum. These cases provide evidence that the Fas/FasL system is closely associated with human GVHD, especially in the development of liver GVHD.</abstract><cop>Oxford, U.K. and Cambridge, USA</cop><pub>Blackwell Science Ltd</pub><pmid>10192442</pmid><doi>10.1046/j.1365-2141.1999.01246.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 1999-03, Vol.104 (4), p.795-800 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69670452 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Wiley Online Library All Journals |
| subjects | Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis BMT, DLT Bone Marrow Transplantation - methods Fas Ligand Protein FasL gene expression Female Graft vs Host Disease - etiology GVHD Humans Leukemia - therapy Lymphocyte Transfusion - adverse effects Male Medical sciences Membrane Glycoproteins - genetics Membrane Glycoproteins - metabolism Monocytes - metabolism Recurrence RNA, Messenger - metabolism sFasL Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A20%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Levels%20of%20soluble%20FasL%20and%20FasL%20gene%20expression%20during%20the%20development%20of%20graft%E2%80%90versus%E2%80%90host%20disease%20in%20DLT%E2%80%90treated%20patients&rft.jtitle=British%20journal%20of%20haematology&rft.au=Das,%20Hiranmoy&rft.date=1999-03&rft.volume=104&rft.issue=4&rft.spage=795&rft.epage=800&rft.pages=795-800&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1046/j.1365-2141.1999.01246.x&rft_dat=%3Cproquest_cross%3E69670452%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69670452&rft_id=info:pmid/10192442&rfr_iscdi=true |